Spyre Therapeutics (SYRE) Change in Intangibles (2025 - 2026)
Spyre Therapeutics posted quarterly Change in Intangibles of $30.0 million for Q1 2026, up 328.57% on a QoQ basis from $7.0 million in Q2 2025.
Spyre Therapeutics (SYRE) has 2 years of Change in Intangibles data on file, last reported at $30.0 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Intangibles changed N/A year-over-year to $30.0 million; the trailing twelve-month figure through Mar 2026 stood at $37.0 million (changed N/A YoY), and the FY2025 full-year result was $7.0 million, changed N/A from the prior year.
- Change in Intangibles for Q1 2026 stood at $30.0 million, up from $7.0 million in the prior quarter.
- Across five years, Change in Intangibles topped out at $30.0 million in Q1 2026 and bottomed at $7.0 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 68,980.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | 30.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.00 Mn |
| Mar 31, 2026 | 30.00 Mn |
| Jun 30, 2025 | 7.00 Mn |
| Jun 30, 2025 | 7.00 Mn |